Editas Medicine, Inc. (EDIT)
3.075
+0.02
(+0.49%)
USD |
NASDAQ |
Sep 01, 16:00
3.07
0.00 (0.00%)
After-Hours: 19:41
Editas Medicine Total Long Term Debt (Quarterly) : 64.74M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 64.74M |
| March 31, 2026 | 65.28M |
| December 31, 2025 | 70.68M |
| September 30, 2025 | 72.63M |
| June 30, 2025 | 71.66M |
| March 31, 2025 | 17.97M |
| December 31, 2024 | 20.38M |
| September 30, 2024 | 22.10M |
| June 30, 2024 | 20.51M |
| March 31, 2024 | 21.78M |
| December 31, 2023 | 24.37M |
| September 30, 2023 | 24.92M |
| June 30, 2023 | 26.86M |
| March 31, 2023 | 28.81M |
| December 31, 2022 | 32.86M |
| September 30, 2022 | 9.328M |
| June 30, 2022 | 10.11M |
| March 31, 2022 | 12.96M |
| December 31, 2021 | 16.07M |
| September 30, 2021 | 18.43M |
| June 30, 2021 | 21.28M |
| March 31, 2021 | 21.62M |
| December 31, 2020 | 19.32M |
| Date | Value |
|---|---|
| September 30, 2020 | 20.37M |
| June 30, 2020 | 22.15M |
| March 31, 2020 | 21.53M |
| December 31, 2019 | 23.28M |
| September 30, 2019 | 13.20M |
| June 30, 2019 | 13.78M |
| March 31, 2019 | 14.86M |
| December 31, 2018 | 32.42M |
| September 30, 2018 | 32.69M |
| June 30, 2018 | 32.94M |
| March 31, 2018 | 33.19M |
| December 31, 2017 | 33.43M |
| September 30, 2017 | 33.67M |
| June 30, 2017 | 33.88M |
| March 31, 2017 | 33.93M |
| December 31, 2016 | 35.10M |
| September 30, 2016 | 32.05M |
| June 30, 2016 | 22.68M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Recursion Pharmaceuticals, Inc. | 53.39M |
| Geron Corp. | 250.76M |
| Halozyme Therapeutics, Inc. | 2.147B |
| Novavax, Inc. | 297.32M |
| AVITA Medical, Inc. | 48.48M |